TARS News and Press, Tarsus Pharmaceuticals Inc. From 05/03/21

Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans Atlas study shows that Demodex blepharitis negatively impacts daily life for 80 percent of patients Tarsus also presents complete efficacy and safety data from Phase 2b Europa tri...

IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye car...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...

Tarsus Pharmaceuticals (TARS): FY GAAP EPS of -$4.32 misses by $2.05.Cash and cash equivalents of $168.1MPress Release For further details see: Tarsus Pharmaceuticals EPS misses by $2.05

Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021 Strategic partnership with LianBio in March 2021 for TP-03 in Greater China provides Tarsus with $70 million expected during next 12 m...

Tarsus Pharmaceuticals (TARS) and biotechnology company and LianBio announce a strategic partnership to develop and commercialize eye treatment TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau).TP-03 is a first-in-class investigational therape...

IRVINE, Calif., SHANGHAI, China and PRINCETON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China a...

IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, startin...

IRVINE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, startin...

Tarsus Pharmaceuticals (TARS) announces that it has received the written minutes of the (Type C) meeting held on December 8 with the FDA on specific NDA submission requirements for TP-03.NDA relates to TP-03 as a treatment for Demodex blepharitis, a common ocular condition with 45% or 9M...